Nison Badalov, MD
Gastroenterology · Brooklyn, NYNPI 1417141664
Payments from drug & device makers
Across 602 payments — averaging $331.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$124K
- AbbVie$59K
- Redhill Biopharma Inc.$7K
- Phathom Pharmaceuticals, Inc.$7K
- E.r. Squibb & Sons, L.L.C.$517
- Bristol Myers Squibb$455
- plus $2K from 25 others
What the payments were for
- Consulting fees$4,4702%
- Speaking & faculty fees$172,81587%
- Travel & lodging$9,4675%
- Food & beverage$12,7586%
- Education$1230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 164 | $124,297 |
| AbbVie(2 entities) | 237 | $58,612 |
| Redhill Biopharma Inc. | 23 | $6,656 |
| Phathom Pharmaceuticals, Inc. | 13 | $6,626 |
| E.r. Squibb & Sons, L.L.C. | 4 | $517 |
| Bristol Myers Squibb | 37 | $455 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 31 | $432 |
| Johnson & Johnson | 14 | $348 |
| Pfizer | 14 | $262 |
| Romark Laboratories, LC | 8 | $222 |
| Ardelyx, Inc. | 7 | $198 |
| Aimmune Therapeutics, Inc. | 7 | $137 |
| Seagen Inc. | 1 | $100 |
| Lilly USA, LLC | 5 | $91 |
| Madrigal Pharmaceuticals | 4 | $73 |
| Ferring Pharmaceuticals Inc. | 3 | $70 |
| Intra-sana Laboratories | 3 | $69 |
| Currax Pharmaceuticals LLC | 4 | $61 |
| Nestle Healthcare Nutrition Inc. | 4 | $57 |
| Merck | 3 | $55 |
| Celltrion USA Inc. | 2 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| QOL Medical, LLC | 2 | $37 |
| Novo Nordisk | 2 | $36 |
| Olympus America Inc. | 1 | $23 |
| Vivus LLC | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Braintree Laboratories, Inc. | 1 | $19 |
| Medline Industries LP | 1 | $15 |
| Micro-tech Endoscopy USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$199,633 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 267 | $782,921 |
| ZenpepLipase/Protease/Amylase | 160 | $435,678 |
| XifaxanRifaximin | 37 | $102,994 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 96 | $101,211 |
| IbsrelaTenapanor Hcl | 38 | $83,253 |
| LinzessLinaclotide | 155 | $83,217 |
| VemlidyTenofovir Alafenamide | 48 | $64,987 |
| VoqueznaVonoprazan Fumarate | 47 | $34,110 |
| MounjaroTirzepatide | 12 | $16,264 |
| Dexlansoprazole DrDexlansoprazole | 99 | $14,758 |
| DexilantDexlansoprazole | 29 | $14,241 |
| TrulancePlecanatide | 20 | $13,194 |
| MotegrityPrucalopride Succinate | 11 | $9,267 |
| Lubiprostone | 55 | $7,068 |
| Omeprazole | 592 | $5,727 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $58,612 | $866,138422 claims |
| Aimmune Therapeutics, Inc.Zenpep | $137 | $435,678160 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $432 | $116,18857 claims |
| Ardelyx, Inc.Ibsrela | $198 | $83,25338 claims |
| GileadVemlidy | $124,297 | $64,98748 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $6,626 | $34,11047 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant, Motegrity | $43 | $23,50940 claims |
| Lilly USA, LLCMounjaro | $91 | $16,26412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in Brooklyn
- Igor GrosmanBrooklyn$2.8M
- Alexander BrunBrooklyn$505K
- Kevin TinBrooklyn$369K
- Sam MoskowitzBrooklyn$332K
- Michael GerdisYonkers$11.9M
- David HudesmanNew York$3.6M
- Ellen ScherlNew York$2.9M
- Bruce SandsNew York$2.8M
- Arun SwaminathNew York$2.7M
- Sonal KumarNew York$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.